View : 594 Download: 0

Velcade (R), Thalidomide, Dexamethasone (VTD) Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Updated Results of Phase II Trial.

Title
Velcade (R), Thalidomide, Dexamethasone (VTD) Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Updated Results of Phase II Trial.
Authors
Eom, HyeonSeokKim, Yeo-KyeoungChung, Joo-SeopKim, KihyunKim, Hyo-JungKim, HoYoungJin, Jong-YoulDo, Young-RokOh, Suk-JoongSuh, CheolwonSeong, Chu-MyongKim, Chul SooLee, Dong SoonLee, Jae Hoon
Ewha Authors
성주명
SCOPUS Author ID
성주명scopus
Issue Date
2008
Journal Title
BLOOD
ISSN
0006-4971JCR Link
Citation
BLOOD vol. 112, no. 11, pp. 962 - 962
Publisher
AMER SOC HEMATOLOGY
Indexed
SCI; SCIE; SCOPUS WOS
Document Type
Meeting Abstract
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE